Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia
Daniel A. Pollyea, Tessa Kerre, Dries Deeren, Y Beguin, Tara L. Lin, David A. Sallman, Sébastien Anguille, William Blum, Anne Flament, Eytan Breman, Caroline Lonez
Topics & Concepts
Myeloid leukemiaMedicineRefractory (planetary science)Myelodysplastic syndromesTolerabilityNKG2DClinical trialCytokine release syndromeMyeloidPersistence (discontinuity)Internal medicineImmunotherapyLeukemiaImmunologyCytokinePhases of clinical researchOncologyChimeric antigen receptorCancer researchAzacitidineAdverse effectClinical significanceLymphomaImmune systemDownregulation and upregulationReceptorGastroenterologyInterferon alfaT cellAntigenCellHematologyAlpha interferonCAR-T cell therapy researchImmune Cell Function and InteractionT-cell and B-cell Immunology